推荐产品
等級
certified reference material
品質等級
形狀
liquid
特點
Snap-N-Spike®/Snap-N-Shoot®
包裝
ampule of 1 mL
製造商/商標名
Cerilliant®
濃度
1.0 mg/mL in methanol
技術
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
應用
clinical testing
格式
single component solution
運輸包裝
wet ice
儲存溫度
−20°C
SMILES 字串
CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCC(O)C5=N1
InChI
1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3
InChI 密鑰
PMXMIIMHBWHSKN-UHFFFAOYSA-N
基因資訊
human ... DRD2(1813) , HTR2A(3356)
一般說明
A Snap-N-Spike® Reference Solution suitable to use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis. Also known as paliperidone, 9-Hydroxyrisperidone is sold under the brand name Invega, an atypical antipsychotic used for acute and maintenance treatment of schizophrenia. The drug is also the primary metabolite of risperidone, marketed as the atypical antipsychotic Risperdal®.
應用
- 9-HydroxyrisperiDonesolution for in vitro research: Employed in pharmacological studies to investigate dual antipsychotic therapies in treatment-resistant conditions, enhancing the understanding of drug interactions and efficacy (Warnick et al., 2024).
- High-purity 9-HydroxyrisperiDoneliquid for pharmacological studies: Utilized in crystallography research to assess the impact of alkyl chain length on the crystallization behavior of related compounds, providing insights into drug formulation strategies (Chen et al., 2024).
- Buy 9-HydroxyrisperiDonesolution for receptor binding assays: Applied in the development of novel drug delivery systems such as dissolving microneedles, enhancing the administration of long-acting antipsychotic treatments (Londhe and Bhadale, 2023).
- 9-HydroxyrisperiDoneactive metabolite for antipsychotic research: Analyzed in postmortem toxicological assessments to identify metabolites, improving forensic analysis techniques and therapeutic drug monitoring (Yamagishi et al., 2023).
- Analytical standard 9-HydroxyrisperiDonefor biochemistry labs: Investigated in the synthesis of prodrug microcrystals for extended-release formulations, aiding in the design of more effective and patient-friendly antipsychotic medications (Xu et al., 2022).
法律資訊
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Risperdal is a registered trademark of Johnson & Johnson
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
訊號詞
Danger
危險分類
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
標靶器官
Eyes
儲存類別代碼
3 - Flammable liquids
水污染物質分類(WGK)
WGK 1
閃點(°F)
49.5 °F - closed cup
閃點(°C)
9.7 °C - closed cup
其他客户在看
Drug and therapeutics bulletin, 50(9), 102-105 (2012-09-12)
For over 40 years, antipsychotic drugs have been used as long-term maintenance treatment to control symptoms and reduce relapse rates in patients with schizophrenia. 'First-generation' oral agents such as haloperidol and chlorpromazine are associated with high levels of unwanted neurological
Paediatric drugs, 14(6), 417-427 (2012-10-12)
Paliperidone, the major active metabolite of risperidone, is an atypical antipsychotic agent formulated as an extended-release (ER) tablet suitable for once-daily oral administration. Paliperidone ER is approved for the treatment of adolescents aged 12-17 years with schizophrenia in the US
Expert review of neurotherapeutics, 12(12), 1399-1410 (2012-12-15)
Paliperidone, or 9-hydroxyrisperidone (Invega(®), Janssen, Antwerp, Belgium) is the major active metabolite of the atypical antipsychotic risperidone (Risperdal(®), Janssen). It possesses a similar, though not identical, receptor pharmacology to the parent molecule. There are additional differences in terms of its
Journal of child and adolescent psychopharmacology, 22(6), 432-439 (2012-12-14)
The aim of this study was to investigate the long-term treatment effects of risperidone on prolactin levels and prolactin-related side effects in pubertal boys with autism spectrum disorders (ASD) and disruptive behavior disorders (DBD). Physical healthy 10-20-year-old males with ASD
Treating residual insomnia in schizophrenia: examining the options.
Acta psychiatrica Scandinavica, 127(1), 11-11 (2012-12-18)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门